Clinical trial
Ologen (OculusGen)-Glaucoma MMC Control in Pakistan
NCT00472810 · Pro Top & Mediking Company Limited, Industry · Completed
Key facts
| NCT number | NCT00472810 |
|---|---|
| Title | Ologen (OculusGen)-Glaucoma MMC Control in Pakistan |
| Official title | Comparative Study of the Safety and Effectiveness Between Ologen (OculusGen) Collagen Matrix Implant and Mitomycin-C in Glaucoma Filtering Surgery |
| Lead sponsor | Pro Top & Mediking Company Limited, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Glaucoma, Trabeculectomy |
| Intervention type | Device, Drug |
| Interventions | ologen collagen matrix in glaucoma filtering surgery, MMC in glaucoma filtering surgery |
| Enrollment | 40 |
| Start date | Mar 1, 2007 |
| Primary completion | May 1, 2008 |
| First posted | May 14, 2007 |
| Last update posted | Oct 7, 2011 |
| Countries | Pakistan |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: